Author

Beata M. Zygmunt

Observed names: Beata M Zygmunt, Beata Zygmunt

Institution: Celon Pharma (Poland)

Observed institutions: Babraham Institute, Celon Pharma (Poland), Helmholtz Centre for Infection Research, Wroclaw Research Centre EIT+ (Poland)

ORCID: 0000-0002-1680-7226

Observed ORCID: 0000-0002-1680-7226

OpenAlex ID: A5063450572

T Helper Cell Differentiation

2011 · Beata Zygmunt, Marc Veldhoen · Advances in immunology · 116

Intranasal Immunization Promotes Th17 Immune Responses

2009 · Beata M Zygmunt, Faiza Rharbaoui, et al. · The Journal of Immunology · 94

Mannose Metabolism Is Essential for Th1 Cell Differentiation and IFN-γ Production

2018 · Beata M Zygmunt, Agnieszka Węgrzyn, et al. · The Journal of Immunology · 15

A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus

2021 · Maria Dulak-Lis, Anna Bujak, et al. · Journal of Pharmacological Sciences · 13

Design, Synthesis, and Development of Pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part II—Benzimidazole Derivatives

2022 · Mariola Stypik, Stanisław Michałek, et al. · Pharmaceuticals · 11

NKT Cell Stimulation with α-Galactosylceramide Results in a Block of Th17 Differentiation after Intranasal Immunization in Mice

2012 · Beata M. Zygmunt, Sebastian F. Weissmann, et al. · PLoS ONE · 11

Development and characterization of attenuated metabolic mutants of Bordetella bronchiseptica for applications in vaccinology

2012 · Tetyana Yevsa, Thomas Ebensen, et al. · Environmental Microbiology · 9

Peritoneal Cavity Is Dominated by IFNγ-Secreting CXCR3+ Th1 Cells

2011 · Beata M. Zygmunt, Lothar Groebe, et al. · PLoS ONE · 8

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

2020 · Paweł Gunerka, Kamila Gala, et al. · PLoS ONE · 7

First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects

2025 · Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, et al. · Frontiers in Pharmacology · 1

Development of Bispecific Antibody Targeting Human IL-17A and IL-6

2026 · Beata Pamuła, Martyna Banach, et al. · Antibodies

Works count: 11

Citation count: 285

H-index: 8

I10-index: 6